ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 446

Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-Risk for Future Rheumatoid Arthritis

Gregory M. Ingolia1, M. Kristen Demoruelle2, Mark C. Parish2, Ryan W. Gan3, Jason R. Kolfenbach2, Michael H. Weisman4, Jane H. Buckner5, Peter K. Gregersen6, Ted R. Mikuls7, James R. O'Dell8, Richard M. Keating9, Alvin Yee10, Michael Mahler10, Jill M. Norris3, Kevin D. Deane2 and V. Michael Holers11, 1University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 3Epidemiology, Colorado School of Public Health, Aurora, CO, 4Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 7University of Nebraska Medical Center, Omaha, NE, 8Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 9Division of Rheumatology, Scripps Clinic, La Jolla, CA, 10Research, INOVA Diagnostics, San Diego, CA, 11Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: autoantibodies and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Immunoglobulin A (IgA) autoantibodies (Abs) to citrullinated proteins (ACPAs) are present in the preclinical period of RA development, a finding that suggests a mucosal site of Ab generation (Kokkonen 2011). IgA ACPAs have also been found in subjects at-risk for future RA based on a family history of disease (Arlestig 2012; Barra 2013). In addition, we have identified apparent local lung mucosal generation of IgA RA-related Abs in at-risk subjects (Willis, Demoruelle 2013). Additional findings that serum IgA ACPA predominates during the early natural history of RA would further support initial mucosal generation of RA-related autoimmunity.

Methods

Three groups from the Studies of the Etiology of RA (SERA) project were evaluated: 77 AtRisk subjects who were first-degree relatives of patients with RA or subjects identified through health fair screening and all were serum positive for ³1 Ab including CCP2 (IgG, Axis-Shield), CCP3.1 (IgG/IgA, INOVA) and rheumatoid factor IgA/M/G (INOVA) without inflammatory arthritis, 53 subjects with seropositive RA (1987 criteria), and 71 blood donor controls. Each subject was tested for ACPA IgA/M/G using CCP3 antigen ELISAs (research use only; donated by INOVA), and by a technician blinded to group status. Positivity for CCP isotypes was mean levels +2 standard deviations in a separate set of 70 random blood donors. Shared epitope (SE) status was determined in AtRisk and RA subjects using published methods (Kolfenbach 2009).

Results

When comparing isotype proportions, IgA-CCP was positive in a higher number of AtRisk subjects than IgM (46.8% vs. 27.3%, p=0.03)(Table), and the prevalence was higher than IgG, although this was not statistically significant (46.8% vs. 39.0%; p=0.33). In contrast, in RA IgG-CCP was more common than IgA and IgM (86.8% vs. 69.8% and 47.2%, respectively; p’s²0.03). In Controls, IgA-CCP was also positive in a higher number of subjects than IgM or G (12.7% vs. 2.8% and 1.4%, respectively; p’s²0.03). In AtRisk, smoking was associated with positivity for ³1 CCP isotype; this was not seen in RA, however, RA subjects were more likely to be current smokers than AtRisk. In AtRisk and RA there was no association between CCP isotypes the SE.

Conclusion

The high IgA ACPA positivity in AtRisk and high IgG APCA in RA suggest that mucosal processes may be an early feature of RA-related autoimmunity that later transition to an IgG-dominant process. IgA ACPA positivity in controls also suggests that IgA-CCP is present in wider populations and perhaps related to non-disease-specific immune responses. These findings as well as the association of smoking with ACPA isotypes in AtRisk subjects and current smoking with RA status need exploration in larger studies that examine the genetic, environmental and mucosal factors that may be involved in the evolution of ACPA isotypes in transition from preclinical to clinically apparent RA.

Controls

AtRisk

RA

N

71

77

53

Age* (mean, SD)

54.9 (12.5)

50.3 (14.5)

58.5 (14.1)

%Female*

79%

71%

83%

%Non-Hispanic White*

–

71%

85%

Ever smoker*

–

36%

45%

Current smoker*

–

8%

45%

³1 allele with the shared epitope (SE)*

–

56%

76%

Proportions of CCP positive subjects using commercial assays

CCP2 (Axis-Shield)**

0.0%

18.2%

83.0%

CCP3.1 (INOVA)**

0.0%

51.9%

84.9%

Proportions of CCP isotype positive subjects

IgA ACPA**

12.7%

46.8%

69.8%

IgM ACPA **

2.8%

27.3%

47.2%

IgG ACPA **

1.4%

39.0%

86.8%

³1 ACPA isotype

16.9%

75.3%

88.7%

Comparisons of proportions of CCP isotype positivity within groups

IgA ACPA vs. IgM

12.7% vs. 2.8%; p=0.03

46.8% vs. 27.3%; p=0.01

69.8% vs. 47.2%; p=0.02

IgA ACPA vs. IgG

12.7 vs. 1.4%; p=0.01

46.8% vs. 39.0%; p=0.33

–

IgG ACPA vs. IgA

–

–

86.8% vs. 69.8%; p=0.03

IgG ACPA vs. IgM

1.45 vs. 2.8%; p=0.56

39.0% vs. 27.3%; p=0.12

86.8% vs. 47.2%; p<0.01

*Race, smoking and SE status were unavailable for blood donor controls; none of the AtRisk or RA subjects were related. The mean age of AtRisk subjects was less than than RA (p<0.01) although there were no significant differences in groups in sex or race. RA subjects were more likely to be current smokers and have ³1 allele with the SE when compared to AtRisk (p<0.05).

**Positivity for all autoantibodies was significantly higher in RA than other groups, and higher in AtRisk when compared to controls. Within the AtRisk subjects, smoking was associated with positivity for ³1 ACPA isotype (odds ratio 2.4; 95% CI 1.2-33.3; p<0.01); in RA, there was no significant association between smoking and any specific ACPA isotype. In AtRisk and RA, there was no association between any ACPA isotype and the presence of ³1 SE allele.


Disclosure:

G. M. Ingolia,
None;

M. K. Demoruelle,
None;

M. C. Parish,
None;

R. W. Gan,
None;

J. R. Kolfenbach,
None;

M. H. Weisman,
None;

J. H. Buckner,
None;

P. K. Gregersen,
None;

T. R. Mikuls,
None;

J. R. O’Dell,
None;

R. M. Keating,
None;

A. Yee,

Inova Diagnostics, Inc.,

3;

M. Mahler,

Inova Diagnostics, Inc.,

3;

J. M. Norris,
None;

K. D. Deane,
None;

V. M. Holers,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunoglobulin-a-antibodies-to-cyclic-citrullinated-protein-predominate-in-individuals-at-risk-for-future-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology